Sanofi (FRA:SNW) DeferredTaxAndRevenue: €0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:SNW Sanofi SA FRA:SNW
89 GF Score
Price €76.75
GF Value €106.88
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Sanofi DeferredTaxAndRevenue?

Sanofi FRA:SNW +0.95% 89 DeferredTaxAndRevenue is €0 Mil as of Dec. 2025. GuruFocus rates FRA:SNW with a GF Score™ of 89/100 and a GF Value™ of €106.88 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Sanofi's current deferred tax and revenue for the quarter that ended in Dec. 2025 was €0 Mil.

Sanofi DeferredTaxAndRevenue Related Terms

Sanofi DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Sanofi's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi DeferredTaxAndRevenue Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 319.00 269.00 0.00 0.00 0.00

Sanofi Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:SNW
89GF Score
Sanofi SA FRA:SNW
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of €0 Mil mean?
Sanofi (FRA:SNW) has a DeferredTaxAndRevenue of €0 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Sanofi.
Is Sanofi's DeferredTaxAndRevenue too high?
Sanofi's current DeferredTaxAndRevenue is €0 Mil. Overall, Sanofi has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi's DeferredTaxAndRevenue compare to LLY and JNJ?
Sanofi's DeferredTaxAndRevenue of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Drug Manufacturers company?
A good DeferredTaxAndRevenue depends on the Drug Manufacturers industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Sanofi. Sanofi's current DeferredTaxAndRevenue is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Based on GuruFocus' analysis, Sanofi (FRA:SNW) is currently considered Modestly Undervalued. The stock's GF Value™ is €106.88, compared to a current price of €76.75 — trading 28.2% below its estimated fair value. The current DeferredTaxAndRevenue is €0 Mil. Sanofi's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Sanofi (FRA:SNW), the current DeferredTaxAndRevenue is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (FRA:SNW) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of €76.75 is trading 28.2% below its estimated GF Value™ of €106.88. GuruFocus considers Sanofi to be Modestly Undervalued.

Key valuation signals for FRA:SNW:

  • DeferredTaxAndRevenue: €0 Mil
  • GF Value™: €106.88 vs. price of €76.75 (28.2% below fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the FRA:SNW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
89GF Score

Get the complete analysis for FRA:SNW

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€76.75
Price
€106.88
GF Value